M
Mathilde Latil
Researcher at University of Paris
Publications - 13
Citations - 288
Mathilde Latil is an academic researcher from University of Paris. The author has contributed to research in topics: Skeletal muscle & Receptor. The author has an hindex of 5, co-authored 13 publications receiving 220 citations. Previous affiliations of Mathilde Latil include Pasteur Institute & Versailles Saint-Quentin-en-Yvelines University.
Papers
More filters
Journal ArticleDOI
Skeletal muscle stem cells adopt a dormant cell state post mortem and retain regenerative capacity
Mathilde Latil,Mathilde Latil,Mathilde Latil,Pierre Rocheteau,Laurent Châtre,Serena Sanulli,Serena Sanulli,Sylvie Mémet,Sylvie Mémet,Miria Ricchetti,Shahragim Tajbakhsh,Fabrice Chrétien,Fabrice Chrétien +12 more
TL;DR: The isolation of viable and functional skeletal myogenic cells from humans up to 17 days, and mice up to 14 days post mortem, much longer beyond previous reports are reported, suggesting a selective survival advantage compared with other cell types.
Journal ArticleDOI
Normal muscle regeneration requires tight control of muscle cell fusion by tetraspanins CD9 and CD81.
Stéphanie Charrin,Mathilde Latil,Mathilde Latil,Mathilde Latil,Sabrina Soave,Sabrina Soave,Anna Polesskaya,Anna Polesskaya,Fabrice Chrétien,Fabrice Chrétien,Claude Boucheix,Claude Boucheix,Eric Rubinstein,Eric Rubinstein +13 more
TL;DR: This study unveils a mechanism preventing inappropriate fusion of myotubes that has an important role in the restitution of normal muscle architecture during muscle regeneration.
Journal ArticleDOI
Beyond AREDS Formulations, What Is Next for Intermediate Age-Related Macular Degeneration (iAMD) Treatment? Potential Benefits of Antioxidant and Anti-inflammatory Apocarotenoids as Neuroprotectors
TL;DR: It is shown that these apocarotenoids preserved more effectively RPE cells against apoptosis following blue light exposure in the presence of A2E than lutein and zeaxanthin in AREDS2, to reduce the incidence of both forms of late AMD.
Journal ArticleDOI
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Waly Dioh,M. Chabane,C. Tourette,A Azbekyan,C Morelot-Panzini,L A Hajjar,M Lins,G B Nair,Tony Whitehouse,J Mariani,Mathilde Latil,Serge Camelo,René Lafont,Pierre J. Dilda,Stanislas Veillet,S. Agus +15 more
TL;DR: Biophytis et al. as mentioned in this paper developed BIO101 (20-hydroxyecdysone, a Mas receptor activator) as a new treatment option for managing patients with SARS-CoV-2 infection at the severe stage.
Journal ArticleDOI
Developing new drugs that activate the protective arm of the renin-angiotensin system as a potential treatment for respiratory failure in COVID-19 patients.
TL;DR: In this paper, the authors reviewed clinical strategies that are attempting to rebalance the renin-angiotensin system (RAS) in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients.